Yamanaka Shinya
Center for iPS Cell Research & Application, Kyoto University, Kyoto 606-8507, Japan.
Philos Trans R Soc Lond B Biol Sci. 2008 Jun 27;363(1500):2079-87. doi: 10.1098/rstb.2008.2261.
Embryonic stem cells are promising donor cell sources for cell transplantation therapy, which may in the future be used to treat various diseases and injuries. However, as is the case for organ transplantation, immune rejection after transplantation is a potential problem with this type of therapy. Moreover, the use of human embryos presents serious ethical difficulties. These issues may be overcome if pluripotent stem cells are generated from patients' somatic cells. Here, we review the molecular mechanisms underlying pluripotency and the currently known methods of inducing pluripotency in somatic cells.
胚胎干细胞是细胞移植治疗中很有前景的供体细胞来源,未来可能用于治疗各种疾病和损伤。然而,与器官移植的情况一样,这种治疗方式移植后的免疫排斥是一个潜在问题。此外,使用人类胚胎存在严重的伦理困境。如果能从患者的体细胞中产生多能干细胞,这些问题或许可以得到解决。在此,我们综述了多能性的分子机制以及目前已知的诱导体细胞多能性的方法。